Systemic therapy options in BRCA mutation-associated breast cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• BRCA mutations impair DNA repair, leading to specific breast cancer subtypes like basal-like.
• BRCA carriers traditionally receive standard chemotherapy, assuming similar prognoses to sporadic cases.
• Emerging research highlights distinct tumor biology in BRCA-associated cancers, necessitating personalized treatment.

Purpose of the Study:

• To review the functions of BRCA1 and BRCA2 genes.
• To explore the differential chemosensitivity of BRCA-associated breast cancers.
• To discuss tailored treatment strategies for BRCA mutation carriers.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of BRCA gene functions in DNA repair.
• Evaluation of chemosensitivity data for various chemotherapy regimens.

Main Results:

• BRCA-associated tumors exhibit sensitivity to platinum compounds and PARP inhibitors.
• BRCA1-mutation carriers may benefit from anthracycline-taxane regimens, similar to sporadic triple-negative breast cancers.
• Optimal chemotherapy regimens for BRCA carriers require further determination.

Conclusions:

• BRCA-associated breast cancers have unique biochemical characteristics due to DNA repair deficiencies.
• Targeted therapies like platinum compounds and PARP inhibitors show promise.
• Further research is needed to establish the optimal chemotherapy regimen for BRCA mutation carriers.